Results 31 to 40 of about 4,527,801 (246)

Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity

Biomedicines, 2022
The development of anti-drug antibodies represents a significant barrier to the utilization of protein-based therapies for a wide variety of diseases.
Patricia E. Zerra, Ernest T. Parker, Wallace Hunter Baldwin, John F. Healey, Seema R. Patel, James W. McCoy, Courtney Cox, Sean R. Stowell, Shannon L. Meeks   +8 more
doaj   +1 more source

Polyethylene Glycol‐Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart

Advanced Science, 2022
Protein therapeutics, except for antibodies, have a short plasma half‐life and poor stability in circulation. Covalent coupling of polyethylene glycol (PEG) to protein drugs addresses this limitation.
Imran Ozer, Garrett Kelly, Renpeng Gu, Xinghai Li, Nikita Zakharov, Parul Sirohi, Smita K. Nair, Joel H. Collier, Michael S. Hershfield, Angus M. Hucknall, Ashutosh Chilkoti   +10 more
doaj   +1 more source

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad, Ohad Atia, Osama Tanous, Dafna Brik Simon, Michal Dvori, Miriam Cohen, Tracie A. Goldberg, Efraim Bilavsky, Joanne Yacobovich, Orna Steinberg‐Shemer   +9 more
wiley   +1 more source

Neonatal alloimmune thrombocytopenia complicated with piperacillin drug antibody: a case report

Zhongguo shuxue zazhi
[Objective] To investigate the clinical symptoms, laboratory tests, and treatment strategies of a case of fetal/neonatal alloimmune thrombocytopenia (FNAIT) complicated with piperacillin drug antibody. [Methods] The platelet antibodies in the mother were
MENG Zifan, ZHANG Shaoqiang, JU Qiang, LI Ying, YAN Songxia, WANG Haiyan   +5 more
doaj   +1 more source

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source

Anti-RhD antibody therapy modulates human natural killer cell function

Haematologica, 2020
Anti-RhD antibodies are widely used in clinical practice to prevent immunization against RhD, principally in hemolytic disease of the fetus and newborn. Intriguingly, this disease is induced by production of the very same antibodies when an RhD negative
Shlomo Elias, Inbal Kol, Shira Kahlon, Rajaa Amore, Mariam Zeibak, Dror Mevorach, Uriel Elchalal, Orly Zelig, Ofer Mandelboim   +8 more
doaj   +1 more source

Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng, Lan Li, Qingmei Yang, Meipeng Wu   +3 more
wiley   +1 more source

Anti-drug antibodies

, 2012
Biological pharmaceuticals are increasingly used in modern medicine and give remarkable improvements for many different patient groups. Unfortunately, for several of these compounds, undesirable immune reactions are induced against the drug.
Fogdell-Hahn, A, Lundkvist, M, Hermanrud, C, Warnke, C   +3 more
core   +1 more source

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review

Frontiers in Immunology
Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in immune-mediated and hematologic diseases, but its efficacy may be limited by the development of anti-rituximab antibodies (ADAs).
Marco Allinovi, Jacopo Lomi, Matteo Accinno, Maxime Teisseyre, Maxime Teisseyre, Maxime Teisseyre, Michael Diomaiuti, Raffaele Madeo, Federica Allegretta, Andrea Matucci, Alessandra Vultaggio   +10 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source